The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Ciprofloxacin and Loperamide in the Treatment of Bacillary Dysentery

Gerald S. Murphy, MD; Ladaporn Bodhidatta, MD; Peter Echeverria, MD; Somsit Tansuphaswadikul, MD; Charles W. Hoge, MD; Somchai Imlarp, BSc; and Kazumichi Tamura, MD
[+] Article, Author, and Disclosure Information

From Naval Medical Research Unit Number 2, Jakarta, Indonesia; Armed Forces Research Institute of Medical Sciences and Army Institute of Clinical Pathology, Bangkok, Thailand; Bamrasnaradura Hospital, Nonthaburi, Thailand; the National Institute of Health, Tokyo, Japan. Requests for Reprints: Peter Echeverria, MD, Department of Bacteriology, Immunology, and Molecular Genetics, Armed Forces Research Institute of Medical Sciences, APO AP 96546 USA. Acknowledgments: The authors thank Captain Augustus L. Bourgeois, MSC, USN, Captain Kurt Sorenson, MC, USN, Captain Edward C. Oldfield III, MC, USN, and Colonel John W. Boslego, MC, USA, for critique and encouragement; John Travers, MD, of McNeil Consumer Products for providing loperamide and placebo; Roger Echols, MD, Director, Medical Research Anti-Infective Group of Miles Pharmaceutical Corporation, West Haven, Connecticut, for providing ciprofloxacin; Boonchuey Eampokalap for culturing specimens at Bamrasnaradura Hospital; the nurses and technicians at the Armed Forces Research Institute of Medical Sciences and the Bamrasnaradura Hospital, and Chalerm Intkhao for their assistance in this study. Grant Support: By funds provided by the U.S. Army and the U.S. Navy Medical Research and Development Commands.

Copyright 2004 by the American College of Physicians

Ann Intern Med. 1993;118(8):582-586. doi:10.7326/0003-4819-118-8-199304150-00002
Text Size: A A A

Objective: To compare the safety and efficacy of loperamide plus ciprofloxacin with those of ciprofloxacin alone in the treatment of bacillary dysentery.

Design: Double-blind, placebo-controlled, randomized clinical trial.

Setting: Hospital in Thailand.

Participants: Eighty-eight adults with dysentery seeking medical care between November 1990 and February 1992. Patients who had received prior antibiotics or antimotility drugs were excluded.

Intervention: All 88 patients with dysentery were treated with ciprofloxacin, 500 mg twice daily for 3 days. Forty-two of these patients were randomly assigned to receive loperamide, a 4-mg initial dose followed by 2 mg after every loose stool (as many as eight caplets [16 mg] daily), and 46 were randomly assigned to receive placebo.

Measurements: Stools were collected daily until resolution of diarrhea and again after 10 days. The time to passage of the last unformed stool, number of unformed stools, and symptoms were recorded after treatment.

Results: Shigella or enteroinvasive Escherichia coli (53%), Vibrio parahaemolyticus (16%), and Salmonella (7%) were the most common bacterial enteric pathogens identified in 88 patients with dysentery. In patients infected with Shigella or enteroinvasive E. coli, the median duration of diarrhea was 19 hours (25th to 75th percentiles, 6 to 42 hours) for those receiving loperamide plus ciprofloxacin compared with 42 hours (21 to 46 hours) for those receiving ciprofloxacin alone (P = 0.028). The median number of diarrheal stools for those receiving ciprofloxacin and loperamide was 2.0 (1 to 5 stools) compared with 6.5 (2 to 9 stools) for those receiving ciprofloxacin alone (P = 0.016). None of the participants had a temperature greater than 38 C after 24 hours of treatment. None of the patients was infected with the same bacterial enteric pathogen more than 1 day after receiving treatment.

Conclusions: Loperamide decreases the number of unformed stools and shortens the duration of diarrhea in dysentery caused by Shigella in adults treated with ciprofloxacin.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.